Yttrium 90-labelled edotreotide is under clinical development by Progenics Pharmaceuticals and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Yttrium 90-labelled edotreotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Yttrium 90-labelled edotreotide overview

Onalta (edotreotide Labeled Yttrium 90) is under development for the treatment of neuroblastoma, medulloblastoma and meningioma. The drug candidate is administered as intravenous and intra-arterial infusion. Onalta (yttrium-90 radiolabeled edotreotide) is a radiolabeled somatostatin analog. The compound has potential to selectively deliver yttrium-90, which is a lethal radiation to cancer cells. Onalta binds selectively to tumor cells that have somatostatin receptors type 2 and 5. The drug candidate was also under development for the treatment of small-cell lung cancer, metastatic breast cancer and neuroendocrine tumors.

Progenics Pharmaceuticals overview

Progenics Pharmaceuticals (Progenics) is a biopharmaceutical company.

For a complete picture of Yttrium 90-labelled edotreotide’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.